WS-SK TARGET (08427) released its annual results, reporting a loss attributable to shareholders of 1.927 million ringgit, reversing from a profit in the same period last year.

21:02 31/08/2026

Wanshun Ruiqiang Group (08427) announced its annual performance for the year ending May 31, 2026, reporting revenues of 34.522 million ringgit, representing a year-on-year increase of 9.4%. The loss attributable to owners of the company was 1.927 million ringgit, compared to a profit of 82,000 ringgit in the same period last year; loss per share was 11.71 sen.

WS-SK TARGET (08427) announced its annual performance for the year ending May 31, 2026. The group achieved revenue of RM 34.522 million, an increase of 9.4% year-on-year; the loss attributable to the owners of the company was RM 1.927 million, compared to a profit of RM 0.082 million in the same period last year; the loss per share was 11.71 sen.

Shanghai RAAS Blood Products (002252.SZ): The SR604 injection is proposed to be included in the Care Program - Extension pilot project.

After a ten-week hiatus, Strategy (MSTR.US) has restarted buying, investing $370 million to increase its holdings in Bitcoin.

HIGHTIDE-B (02511) announced its interim results, reporting a loss attributable to shareholders of approximately 146 million yuan, a year-on-year increase of 21.43%.

Shanghai RAAS Blood Products (002252.SZ): The SR604 injection is proposed to be included in the Care Program - Extension pilot project.

After a ten-week hiatus, Strategy (MSTR.US) has restarted buying, investing $370 million to increase its holdings in Bitcoin.

HIGHTIDE-B (02511) announced its interim results, reporting a loss attributable to shareholders of approximately 146 million yuan, a year-on-year increase of 21.43%.